Moderna (MRNA)
(Delayed Data from NSDQ)
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $161.32, marking a +0.56% move from the previous day.
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.
Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids
by Zacks Equity Research
Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $169.61, moving -1.81% from the previous trading session.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Earnings Data to Flood Wall Street This Week
by Zacks Equity Research
Earnings Data to Flood Wall Street This Week.
Good Riddance to a Rough Trading Month
by Mark Vickery
It would be easy to forget we started out its first few trading days notching new all-time highs on both the Dow and the S&P 500.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J
by Zacks Equity Research
Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $157.30 in the latest trading session, marking a -1.73% move from the prior day.
4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
by Zacks Equity Research
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.
Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?
by Zacks Equity Research
Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.
AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron
by Zacks Equity Research
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.